由于分析师评级不一致,收益符合预期,正在进行的第三阶段试验和待定证券诉讼等原因,2026年初Mereo BioPharma股价跌至0.34美元. Mereo BioPharma's stock fell to $0.34 in early 2026 amid mixed analyst ratings, earnings meeting expectations, ongoing Phase 3 trials, and pending securities lawsuits.

梅雷奥生物制药集团 (NASDAQ:MREO) 在2026年初获得了分析师的混合评级,Lifesci Capital升级为"持有",而其他公司则发布了"买入"",卖出"或"超重"观点,导致共识性"持有的"评价和3.25美元的目标价格. Mereo BioPharma Group (NASDAQ:MREO) received mixed analyst ratings in early 2026, with Lifesci Capital upgrading to "hold" while others issued "buy," "sell," or "overweight" views, resulting in a consensus "hold" rating and a $3.25 price target. 该公司报告了2025年第四季度每股收益为0.01美元,符合预期,此前的收入不足0.05美元,并强调正在进行对骨质不完善症中setrusumab (UX143) 的第三阶段数据分析. The company reported Q4 2025 earnings of ($0.01) per share, meeting expectations after a prior miss of ($0.05), and highlighted ongoing Phase 3 data analyses for setrusumab (UX143) in osteogenesis imperfecta. 该股票的交易价格为0.34美元,市值5442万美元.由于2023年6月至2025年12月期间在ADS购买多项证券集体诉讼而面临法律不确定性,主要原告截止时间是2026年4月6日. The stock trades at $0.34 with a $54.42 million market cap and faces legal uncertainty due to multiple securities class action lawsuits over ADS purchases from June 2023 to December 2025, with a lead plaintiff deadline of April 6, 2026.